The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Andrew H. Wei(The Royal Melbourne Hospital), Gail J. Roboz(Cornell University), Pau Montesinos(Instituto de Salud Carlos III), Chiara Frairia(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), C.L. Beach(Université Paris Cité), Boris V. Afanasyev(First Pavlov State Medical University of St. Petersburg), Justyna Rybka(Hospital Universitari i Politècnic La Fe), Yishai Ofran(Shaare Zedek Medical Center), Christopher Pocock(East Kent Hospitals University NHS Foundation Trust), Dominik Selleslag(National Institutes of Health), Jun Ho Jang(Samsung Medical Center), Irwindeep Sandhu(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Hamid Sayar(Hospital Universitari i Politècnic La Fe), Kimmo Porkka(Helsinki University Hospital), Valentina Giai(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Ignazia La Torre(Hospital Universitari i Politècnic La Fe), Jaroslav Čermák(Hospital Universitari i Politècnic La Fe), Hartmut Döhner(University Hospital Ulm), Qian Dong(Liaoning Cancer Hospital & Institute), Mehmet Turgut(Hospital Universitari i Politècnic La Fe), Merih Kızıl Çakar(Ankara Onkoloji Eğitim ve Araştırma Hastanesi), Keshava Kumar(Hospital Universitari i Politècnic La Fe), Aïda Botelho de Sousa(Hospital Universitari i Politècnic La Fe), Gert J. Ossenkoppele(Dutch Cancer Society), Lorenza Borin(Azienda Ospedaliera San Gerardo), Barry Skikne(Boston Children's Hospital), Hervé Dombret(University of London Institute in Paris), Germana Beltrami(Hospital Universitari i Politècnic La Fe), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 97
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k